These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 1793066

  • 1. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo.
    Alabaster VA, Keir RF, Parry MJ, de Souza RN.
    Agents Actions Suppl; 1991; 34():221-7. PubMed ID: 1793066
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
    Parry MJ, Alabaster VA, Cheeseman HE, Cooper K, deSouza RN, Keir RF.
    J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH.
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [Abstract] [Full Text] [Related]

  • 4. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
    Tsunoda H, Sakuma Y, Harada K, Muramoto K, Katayama S, Horie T, Shimomura N, Clark R, Miyazawa S, Okano K.
    Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
    Casals-Stenzel J, Muacevic G, Weber KH.
    J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913
    [Abstract] [Full Text] [Related]

  • 7. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
    Levrier J, Duval D, Prouteau M, Voltz C, Berry CN, Lloyd KG, Scatton B.
    Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
    Carceller E, Merlos M, Giral M, Balsa D, García-Rafanell J, Forn J.
    J Med Chem; 1996 Jan 19; 39(2):487-93. PubMed ID: 8558517
    [Abstract] [Full Text] [Related]

  • 9. Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412.
    Handley DA, Van Valen RG, Melden MK, Houlihan WJ, Saunders RN.
    J Pharmacol Exp Ther; 1988 Nov 19; 247(2):617-23. PubMed ID: 3183958
    [Abstract] [Full Text] [Related]

  • 10. Effects of a new platelet-activating factor antagonist, UR-12670, on several endotoxic shock markers in rats.
    Balsa D, Merlos M, Giral M, Ferrando R, Garcia-Rafanell J, Forn J.
    Drugs Exp Clin Res; 1997 Nov 19; 23(5-6):191-9. PubMed ID: 9515229
    [Abstract] [Full Text] [Related]

  • 11. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
    Hwang SB, Li CL, Lam MH, Shen TY.
    Lab Invest; 1985 Jun 19; 52(6):617-30. PubMed ID: 3925239
    [Abstract] [Full Text] [Related]

  • 12. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
    Komuro Y, Imanishi N, Uchida M, Morooka S.
    Mol Pharmacol; 1990 Sep 19; 38(3):378-84. PubMed ID: 2402227
    [Abstract] [Full Text] [Related]

  • 13. Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
    Curtin ML, Davidsen SK, Heyman HR, Garland RB, Sheppard GS, Florjancic AS, Xu L, Carrera GM, Steinman DH, Trautmann JA, Albert DH, Magoc TJ, Tapang P, Rhein DA, Conway RG, Luo G, Denissen JF, Marsh KC, Morgan DW, Summers JB.
    J Med Chem; 1998 Jan 01; 41(1):74-95. PubMed ID: 9438024
    [Abstract] [Full Text] [Related]

  • 14. WEB 2347: pharmacology of a new very potent and long acting hetrazepinoic PAF-antagonist and its action in repeatedly sensitized guinea-pigs.
    Heuer HO.
    J Lipid Mediat; 1991 Jan 01; 4(1):39-44. PubMed ID: 1893086
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.
    Fernández-Gallardo S, Ortega MP, Priego JG, de Casa-Juana MF, Sunkel C, Sánchez Crespo M.
    J Pharmacol Exp Ther; 1990 Oct 01; 255(1):34-9. PubMed ID: 2170626
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist.
    Wu MS, Biftu T, Doebber TW.
    J Pharmacol Exp Ther; 1986 Dec 01; 239(3):841-5. PubMed ID: 3795043
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor.
    Yamada T, Tomioka K, Saito M, Horie M, Mase T, Hara H, Nagaoka H.
    Arch Int Pharmacodyn Ther; 1990 Dec 01; 308():123-36. PubMed ID: 2099131
    [Abstract] [Full Text] [Related]

  • 18. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM, Fraisse L, Bachy A, Valette G, Savi P, Laplace MC, Lassalle J, Roche B, Lale A, Keane PE.
    J Lipid Mediat; 1993 Aug 01; 8(1):31-51. PubMed ID: 8257776
    [Abstract] [Full Text] [Related]

  • 19. Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
    Fray MJ, Bull DJ, Cooper K, Parry MJ, Stefaniak MH.
    J Med Chem; 1995 Sep 01; 38(18):3524-35. PubMed ID: 7658439
    [Abstract] [Full Text] [Related]

  • 20. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.
    Doebber TW, Wu MS, Biftu T.
    J Immunol; 1986 Jun 15; 136(12):4659-68. PubMed ID: 3011900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.